DOT1L and leukemia: Therefore, medicinal chemistry efforts for DOT1L inhibition have led to the first HMTi in clinics, compound (29) that completed phase I clinical trials for leukemia treatment and myelodysplastic syndromes (NCT02141828, NCT01684150).